Opens in a new tab

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job

Labcorp and Thrive Global have launched a $159 direct-to-consumer test built around five cardiometabolic measures: apolipoprotein B, high-sensitivity C-reactive protein, HbA1c, blood pressure and BMI. Every measure has legitimate clinical relevance, but the bundle itself is not a validated cardiovascular risk score and it omits several assessments now central to guideline-based cardiovascular-kidney-metabolic care.

November 4, 2026
Editorial
Consumer laboratory testing can make cardiometabolic risk information easier to access, but interpreting risk still requires clinical context, appropriate follow-up and a broader assessment than any single commercial panel can provide.PeopleImages / Shutterstock.com

IPM Take

Preventive cardiology has spent years trying to persuade people to know their numbers. The consumer-health market is now making those numbers easier to buy.

Labcorp and Thrive Global’s new Thrive 5 Health Test packages five familiar cardiometabolic measures into a $159 consumer product: ApoB, high-sensitivity C-reactive protein, HbA1c, blood pressure and BMI. Results are paired with personalised educational material and small behavioural recommendations covering diet, movement, sleep, stress and social connection.

There is something appealing about the simplicity. ApoB can reveal atherogenic particle burden that conventional cholesterol measures sometimes underestimate. HbA1c captures long-term glycaemia. Blood pressure remains one of the most important modifiable cardiovascular risks. BMI provides a basic measure of body size, while hs-CRP can identify an inflammatory signal relevant to cardiovascular risk in selected patients.

But five useful measurements do not automatically create a complete cardiometabolic assessment.

The 2026 cardiovascular-kidney-metabolic guideline recommends routine attention not only to blood pressure, BMI and glycaemia, but also to waist circumference, conventional lipids and kidney function, with urine albumin testing in people at higher CKM stages. The 2026 dyslipidaemia guideline separately recommends that lipoprotein(a) be measured at least once in adulthood and positions ApoB as an additional risk-refinement tool rather than a universal replacement for the standard lipid profile.

The policy tension is therefore not whether the Thrive 5 measurements matter.

They do.

It is whether the consumerisation of prevention will strengthen existing care pathways or create a parallel marketplace in which patients purchase fragments of risk assessment and are then left to navigate what those numbers mean.

A test can identify a problem.

A prevention system has to make something happen next.

Executive Summary

Labcorp and Thrive Global launched the Thrive 5 Health Test in October 2026 as a consumer-facing cardiometabolic testing package available through Labcorp OnDemand.

The test costs $159, is eligible for HSA and FSA payment and is available to adults through participating Labcorp locations. A healthcare provider reviews and approves the testing request, but no separate clinical visit is required before purchase.

The panel combines five measurements:

Apolipoprotein B (ApoB), which estimates the number of circulating atherogenic lipoprotein particles.

High-sensitivity C-reactive protein (hs-CRP), an inflammatory biomarker that can contribute to cardiovascular risk assessment in specific clinical contexts.

HbA1c, which reflects average glycaemia over approximately two to three months and is established in the diagnosis and monitoring of diabetes and prediabetes.

Blood pressure, a major modifiable cardiovascular risk factor.

Body mass index, a basic anthropometric screening measure derived from height and weight.

Labcorp states that the results are intended to provide information about cardiovascular, inflammatory and metabolic health and are accompanied by Thrive Global educational content and behavioural “Microsteps”. The company also explicitly states that the product does not diagnose disease and is not a substitute for medical advice.

The individual measures have varying positions in clinical guidelines.

The 2026 ACC/AHA dyslipidaemia guideline recommends Lp(a) testing at least once in adulthood, supports selective use of ApoB to refine risk and identifies hs-CRP of at least 2 mg/L on repeated measurement as a risk enhancer in appropriate patients.

The 2026 AHA/ACC/ADA/ASN cardiovascular-kidney-metabolic guideline takes a broader approach. For adults without CKM syndrome, it recommends periodic assessment of lipids, glycaemia and kidney function, alongside annual blood pressure and anthropometric assessment. Higher-risk patients require more frequent testing, with both estimated glomerular filtration rate and urine albumin-to-creatinine ratio becoming important when kidney and metabolic risk increase.

The commercial bundle therefore overlaps substantially with guideline-relevant risk assessment but should not be interpreted as a comprehensive or guideline-defined cardiometabolic screening panel.

Why it matters

  • HTA bodies: Consumer laboratory panels increasingly combine clinically valid biomarkers into proprietary packages, but the evidentiary question is different from whether each individual test works. Assessment needs to ask whether the combination improves risk classification, changes management and ultimately improves outcomes compared with established clinical pathways.
  • Payers: A $159 self-pay panel illustrates both the opportunity and the equity problem in consumerised prevention. People with disposable income can increasingly purchase additional risk information, while populations with the highest cardiometabolic burden may still struggle to access routine blood-pressure, lipid, diabetes and kidney screening. Coverage policy should therefore distinguish between valuable preventive testing and premium packaging of tests that should already be available through primary care.
  • Industry / innovation partners: The commercial opportunity is moving from testing alone toward interpretation and behaviour change. The harder challenge is demonstrating that personalised dashboards and micro-interventions produce sustained improvements in blood pressure, glycaemia, lipids or cardiovascular outcomes rather than simply generating short-term engagement with health data.

The quantified-self era has created an unusual contradiction in preventive medicine.

People can monitor sleep every night, count thousands of steps, watch heart-rate variability change by the hour and order laboratory tests without first sitting in a doctor’s office, yet many of the cardiovascular conditions medicine already knows how to prevent remain poorly detected or inadequately controlled.

Labcorp and Thrive Global are betting that the problem is partly one of complexity.

Their new Thrive 5 Health Test reduces cardiometabolic health to five numbers that consumers can purchase together for $159: ApoB, high-sensitivity C-reactive protein, HbA1c, blood pressure and BMI.

The proposition is deliberately simple. Instead of offering dozens of biomarkers or another dashboard overflowing with data, the test selects measures intended to represent atherosclerotic risk, inflammation, glycaemia, blood pressure and body size, then connects the results with behavioural recommendations through Thrive Global.

That simplicity is commercially attractive.

It is also where the clinical questions begin.

None of the five measures is frivolous.

Blood pressure is one of the most important determinants of cardiovascular disease worldwide and remains inadequately controlled in large parts of the population. HbA1c is deeply embedded in diabetes diagnosis and management. ApoB has gained greater prominence as cardiology increasingly recognises that the number of atherogenic lipoprotein particles can sometimes capture residual risk more effectively than LDL cholesterol concentration alone.

High-sensitivity CRP occupies a more conditional position.

Inflammation is clearly involved in atherosclerosis, and the 2026 ACC/AHA dyslipidaemia guideline recognises persistently elevated hs-CRP as a cardiovascular risk enhancer. In adults with borderline predicted risk, an hs-CRP concentration of at least 2 mg/L on two occasions, with no other identifiable reason for the elevation, can influence preventive treatment decisions.

That is very different from saying that one elevated hs-CRP result means a person has cardiovascular disease.

CRP rises with infection, inflammatory illness and numerous other conditions, which is precisely why context and repeat testing can matter.

BMI has similar interpretive limits.

It remains useful because it is inexpensive, reproducible and associated with cardiometabolic risk at population level. Yet it does not directly measure visceral adiposity, body composition or fat distribution. The 2026 cardiovascular-kidney-metabolic guideline therefore recommends assessing waist circumference alongside BMI rather than assuming BMI alone captures obesity-related metabolic risk.

The important issue is not that Labcorp selected the wrong biomarkers.

It is that there is no clinically established set of exactly five measurements that, together, defines cardiometabolic health.

The package is a commercial curation of useful measures, not a new validated clinical risk algorithm.

That distinction becomes clearer when the test is compared with current cardiovascular guidelines.

The 2026 AHA, ACC, American Diabetes Association and American Society of Nephrology guideline on cardiovascular-kidney-metabolic syndrome treats metabolic risk, kidney disease and cardiovascular disease as an interconnected continuum.

For adults at the lowest CKM stage, the guideline recommends periodic assessment of conventional lipids, glycaemia and kidney function, with blood pressure assessed at least annually. BMI and waist circumference should also be measured regularly.

As cardiometabolic risk rises, the assessment becomes more intensive.

Patients with metabolic risk factors or kidney disease require more frequent testing, and both estimated glomerular filtration rate and urine albumin-to-creatinine ratio become important because kidney disease is not a peripheral issue in contemporary cardiovascular prevention. It can fundamentally change cardiovascular risk and treatment.

None of those kidney measures is included in the Thrive 5 package.

Nor is a conventional lipid panel.

That does not make the product clinically meaningless. ApoB provides valuable information about atherogenic particle burden, but guideline-based lipid management still uses LDL cholesterol, non-HDL cholesterol, triglycerides and overall clinical risk rather than treating ApoB as a universal standalone replacement.

Another increasingly prominent biomarker is missing as well.

The 2026 dyslipidaemia guideline recommends that lipoprotein(a), or Lp(a), be measured at least once in adulthood because elevated levels are largely genetically determined and can substantially increase lifelong atherosclerotic cardiovascular risk.

Labcorp sells Lp(a) separately.

The company’s own Thrive 5 product page lists it among tests that consumers can purchase alongside the panel.

This illustrates the central challenge of consumer laboratory medicine.

Once prevention becomes modular, there is no obvious stopping point.

A person can buy five tests, then add Lp(a), then fasting glucose, then an insulin-resistance test, a comprehensive metabolic panel and eventually a much larger collection of biomarkers.

Every additional number can feel like additional certainty.

That is not always how risk assessment works.

Cardiovascular prevention depends on combining measurements with age, sex, smoking, kidney function, medication use, family history, existing disease and increasingly social determinants of health. The PREVENT equations used in current US cardiovascular guidance explicitly integrate multiple factors rather than asking clinicians to interpret biomarkers independently.

A normal result does not necessarily mean low risk, and an abnormal result does not necessarily require treatment.

The value of a test lies partly in whether the result changes a decision.

That becomes particularly important with direct-to-consumer laboratory testing because the traditional sequence of care is being reversed.

In conventional clinical practice, a physician evaluates the patient, identifies which information is needed and orders testing to answer a specific question.

Consumer testing begins with the test.

Interpretation comes afterwards.

Labcorp has built some safeguards into the model. A healthcare provider reviews and approves the request, and the company makes clear that the test does not diagnose medical conditions. Consumers are encouraged to bring results to their own healthcare provider when additional follow-up is appropriate.

But that creates another question: who owns the abnormal result?

A customer with an elevated ApoB, HbA1c or blood pressure reading may need repeat testing, formal cardiovascular risk estimation, a diagnosis, medication or ongoing monitoring. Those decisions still require a functioning healthcare pathway.

Behaviour-change advice can complement that process.

It cannot replace it.

This is where the Thrive Global component is conceptually interesting.

Preventive medicine is full of numbers that clinicians already know matter, yet translating those numbers into sustained behaviour remains one of its weakest points. Telling someone with rising HbA1c to improve diet, move more and lose weight is easy. Designing daily habits that survive work, stress, poor sleep, family responsibilities and the food environment is much harder.

Thrive’s model attempts to bridge that gap by connecting biomarker results with small behavioural steps around food, movement, sleep, stress and social connection.

The hypothesis is reasonable.

The evidence question is whether those personalised recommendations produce better cardiometabolic outcomes than ordinary test reporting or conventional counselling.

That has not yet been established for the Thrive 5 product.

A commercially available intervention should therefore not be confused with a clinically validated prevention pathway.

The distinction matters because preventive medicine is increasingly moving toward precisely this intersection of diagnostics, consumer technology and behaviour.

Full-body imaging, continuous glucose monitoring in people without diabetes, wearable cardiovascular metrics and large laboratory panels are all competing for consumers who want earlier warning of disease.

Some of that demand reflects a healthy desire for prevention.

Some reflects an understandable anxiety that more data must mean greater control.

The health system’s responsibility is to distinguish the two.

There is also an equity issue hidden inside the enthusiasm for consumer testing.

The United States still struggles with basic hypertension control, diabetes detection and access to primary prevention. Millions of people need nothing more exotic than reliable blood-pressure measurement, a standard lipid profile, glycaemic testing and access to treatment.

Against that background, a $159 consumer panel raises an uncomfortable policy question.

Is preventive medicine becoming easier to purchase than to access?

For an affluent health-conscious consumer, adding ApoB and hs-CRP may refine an already sophisticated understanding of cardiovascular risk.

For someone without reliable primary care, the more important missing intervention may be diagnosis and treatment of ordinary hypertension.

Those are not competing truths.

Consumer testing can expand access for some people while simultaneously highlighting the fragmentation of prevention for others.

The test may even help bring people into care who otherwise would not have engaged with the health system.

But its success should ultimately be judged by what happens after the result arrives.

If a high HbA1c leads to confirmed diabetes and appropriate treatment, the test may have created clinical value. If elevated ApoB leads to proper risk assessment and lipid management, the information becomes actionable.

If the result generates only another dashboard, a recipe and several weeks of behavioural engagement before disappearing into an app, the prevention gap remains.

The same principle applies to normal results.

Five reassuring numbers cannot exclude cardiovascular disease or establish that overall cardiometabolic risk is low, because the panel does not incorporate the full set of factors modern guidelines use to assess risk.

That is why Labcorp’s own disclaimer is important.

The Thrive 5 test provides information.

It is not a diagnosis.

The product therefore captures both the promise and the limitation of consumerised prevention.

It makes meaningful health data easier to obtain and attempts to translate those data into action. That is a real advance over collecting numbers without interpretation.

At the same time, cardiometabolic health cannot ultimately be reduced to five biomarkers, just as prevention cannot be reduced to purchasing a test.

The future of prevention may involve easier access to personal health data. The measure of success will not be how many numbers consumers can buy, but how reliably abnormal risk is converted into effective care.

Source & Evidence